Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use

Olipudase alfa (Xenpozyme™) is an intravenously administered acid sphingomyelinase enzyme replacement therapy indicated to treat non-CNS manifestations of acid sphingomyelinase deficiency (ASMD) in adult and paediatric patients. It is the first and currently the only disease-modifying treatment for...

Descripción completa

Detalles Bibliográficos
Autor principal: Syed, Yahiya Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Adis Drug Q&A
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361862/
https://www.ncbi.nlm.nih.gov/pubmed/37133675
http://dx.doi.org/10.1007/s40261-023-01270-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361862/
https://www.ncbi.nlm.nih.gov/pubmed/37133675
http://dx.doi.org/10.1007/s40261-023-01270-x

Ejemplares similares